Physician profile
Allison Jarrett
NPI 1841882834
$10,269.53
in general payments reported to CMS, 2019-2025
62 companies · $3,413 in 2025
The $3,413 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $1,416 · 2023: $1,708 · 2024: $3,321 · 2025: $3,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,179 · Long Term Medical Supply Or Device Loan: $2,164 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,179.06 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,097.39 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $551.45 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $547.31 | 2022-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $452.58 | 2022-2025 | Opdivo |
| Janssen Biotech, INC. | $369.72 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $330.74 | 2022-2025 | Enhertu, Vanflyta, Injectafer |
| Pfizer INC. | $328.65 | 2022-2025 | |
| Eisai INC. | $265.98 | 2021-2025 | |
| Astellas Pharma US INC | $219.42 | 2021-2024 | Padcev, Xospata |
| Genzyme Corporation | $214.09 | 2022-2025 | |
| Abbvie INC. | $199.51 | 2022-2025 | |
| Seagen INC. | $199.21 | 2021-2023 | Padcev, Tukysa |
| Rigel Pharmaceuticals, INC. | $174.35 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Amgen INC. | $170.08 | 2021-2023 | Kyprolis, Lumakras |
| Glaxosmithkline, LLC. | $163.18 | 2021-2025 | Jemperli, Zejula |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $155.27 | 2021-2024 | Jakafi, Monjuvi |
| Lilly USA, LLC | $153.88 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $141.58 | 2021 | |
| Alexion Pharmaceuticals, INC. | $135.29 | 2022-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $134.45 | 2022-2025 | Onivyde, Tazverik, Somatuline Depot |
| Adaptive Biotechnologies Corporation | $134.10 | 2024-2025 | Clonoseq |
| Genentech USA, INC. | $129.76 | 2022-2025 | Polivy, Itovebi, Columvi |
| Jazz Pharmaceuticals INC. | $123.10 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.97 | 2021-2025 | |
| Puma Biotechnology, INC. | $105.10 | 2023-2025 | Nerlynx |
| Regeneron Healthcare Solutions, INC. | $98.62 | 2022-2025 | Libtayo |
| Caris Mpi, INC. | $97.53 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $86.72 | 2024-2025 | Trodelvy |
| Springworks Therapeutics, INC. | $83.92 | 2024-2025 | Ogsiveo, Gomekli |
| Deciphera Pharmaceuticals INC. | $78.43 | 2023-2025 | Qinlock, Romvimza |
| Aveo Pharmaceuticals, INC. | $75.93 | 2023-2025 | Fotivda |
| Stemline Therapeutics INC. | $73.77 | 2024-2025 | Orserdu |
| Blueprint Medicines Corporation | $70.24 | 2022-2025 | Ayvakit |
| Sumitomo Pharma America, INC. | $69.76 | 2024-2025 | Orgovyx |
| Celgene Corporation | $66.41 | 2022-2023 | Pomalyst, Reblozyl, Opdualag |
| Beone Medicines USA, INC. | $64.31 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $61.50 | 2023-2024 | |
| Sobi, INC | $56.52 | 2023-2025 | |
| Beigene USA, INC. | $55.16 | 2023-2025 | Brukinsa |
| Acrotech Biopharma INC. | $49.24 | 2022-2024 | Beleodaq |
| Emd Serono, INC. | $43.75 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.64 | 2024-2025 | Fruzaqla, Ninlaro |
| Servier Pharmaceuticals LLC | $40.99 | 2024-2025 | |
| Pharmaessentia USA Corporation | $39.84 | 2024 | Besremi |
| Coherus Oncology, INC. | $36.51 | 2024 | |
| Pharming Healthcare, INC. | $31.99 | 2024 | Ruconest |
| Syndax Pharmaceuticals, INC. | $27.46 | 2025 | |
| Janssen Pharmaceuticals, INC | $26.44 | 2023 | Xarelto |
| Stryker Corporation | $26.01 | 2025 | Optablate |
| Cti Biopharma Corp. | $24.16 | 2023 | Vonjo |
| Fennec Pharmaceuticals, INC. | $24.10 | 2024 | Pedmark |
| Tersera Therapeutics LLC | $23.27 | 2023 | Quzyttir |
| Acceleron Pharma, INC. | $23.04 | 2021 | |
| Array Biopharma INC | $22.90 | 2025 | Mektovi, Tukysa, Braftovi |
| Alnylam Pharmaceuticals INC. | $22.69 | 2024 | Givlaari |
| Pharmacosmos Therapeutics INC. | $22.22 | 2025 | Monoferric |
| Cardinal Health 414 LLC | $22.17 | 2023 | |
| Taiho Oncology, INC. | $19.56 | 2025 | |
| Novo Nordisk INC | $15.84 | 2022 | |
| Morphosys, US INC. | $15.64 | 2023 | Monjuvi |
| Helsinn Therapeutics (U.S.), INC. | $13.18 | 2023 | Akynzeo |
| Foundation Medicine, INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Jarrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.